Theravance Biopharma’s $100.5 Million Shares Offering

Davis Polk advised the underwriters in the offering.Theravance Biopharma, Inc. executed its $100.5 million public offering of ordinary shares. Theravance Biopharma’s ordinary shares are listed on the Nasdaq Global…